. 2021 Jul 21;8:1530–1537. doi: 10.1016/j.toxrep.2021.07.012

Table 2.

Effect of treatments on breast cancer cell counts in different cell cycle phases.

Groups	Apoptosis	G0/G1 phase	S phase	G2/M phase
Control	6.8 ± 0.6^b	9.4 ± 0.61^b	67.08 ± 0.31 ^b	16.45 ± 0.5 ^b
EP1 agonist	2.13 ± 0.32^a	8.16 ± 0.5^a	71.11 ± 0.82 ^a	18.47 ± 0.76^a
EP1 antagonist + EP1 agonist	22.6 ± 0.71 ^a,b	54.36 ± 0.4 ^{a, b}	15.56 ± 0.3 ^{a, b}	7.57 ± 0.37 ^{a, b}
MEK inhibitor + EP1 agonist	16.46 ± 0.65 ^{a, b}	62.76 ± 0.5 ^{a, b}	17.06 ± 0.67 ^{a, b}	3.87 ± 0.3 ^{a, b}
PKC inhibitor + EP1 agonist	18.27 ± 0.45 ^{a, b}	56.43 ± 0.45 ^{a, b}	17.7 ± 0.9 ^{a, b}	7.73 ± 0.35 ^{a, b}
NF-ҡB inhibitor + EP1 agonist	27.9 ± 0.85 ^{a, b}	56.1 ± 1.05 ^{a, b}	13.13 ± 0.71 ^{a, b}	2.8 ± 0.31 ^{a, b}

Data are presented as mean ± SD. a: Significant versus control group. b: Significant versus EP1 agonist group. n = 3 replicates. EP1: E prostanoid receptor 1, MEK: Mitogen activated protein kinase kinase, PKC: Protein kinase C, NF-ҡB: Nuclear factor kappa-light-chain-enhancer of activated B cells. G0/G1: Gap phase G0 and G1, S: Synthesis phase, G2/M: Gap phase 2 and mitosis phase.